metformin hcl Search Results


94
Selleck Chemicals metformin
Fig. 4. Inhibition of Complex I sensitized the radioresistant glioma U87MG_F cells to radiation. (A) MTT assay was used to test the effects of rotenone on the growth of U87MG and U87MG_F cells. (B) We used 200 nM rotenone to treat U87MG, U87MG_F and U251 cells. This dose of rotenone does not influence the cell growth. The survivals of cells after treating with rotenone and 2 Gy radiation were analyzed, which showed rotenone can sensitize U87MG_F cells to 2 Gy radiation. However, rote- none did not obviously increase the sensitization of U87MG cells to ra- diation. (C) We used 12 mM <t>metformin</t> treat U87MG, U87MG_F and U251 cells. The survivals of cells after treating with metformin and 2 Gy radiation were analyzed, which showed metformin sensitized U87MG_F cells to 2 Gy radiation. These results demonstrate mitochondria meta- bolism play vital roles in fractioned radiation-induced radioresistance of glioma cells. (D) The Complex I inhibitor, rotenone (200 nM), increases the intracellular ROS production in U87MG and U87MG_F cells, while metformin (12 mM) decrease the ROS production. The ROS in control cells was set 1, and fold changes in the drug-treated cells were shown up. ***p < 0.001.
Metformin, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/metformin+hcl/Metformin+HCl/pm32768950-53-2-3
Average 94 stars, based on 1 article reviews
metformin - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
TargetMol metformin
Intestinal ischemia-reperfusion injury induced intestinal barrier disruption and epithelial cell injury. Mice were performed with a temporary occlusion of SMA with an atraumatic vascular for different period and then release the clamp to allow a 120-min reperfusion to build an I/R model. (A) The experimental design of the present work. To evaluate the intestinal injury of different ischemia period, the animals were divided into four groups: the different ischemia period (30,60 and 90 min) group and sham group(n = 6). To determine the protective effect of <t>metformin,</t> another set of animals were administrated with metformin (20 or 40 mg/kg) or saline immediately at the end of a 60-min ischemia period. CY-04 (20 mg/kg), a specific inhibitor of NLRP3 inflammasomes, was used as a positive control for metformin. The OGD/R model was launched in Caco-2 cells. si- Txnip/Gsdmd were applied to revealed the roles of pyroptosis and TXNIP/NLRP3/GSDMD axis in the protective effect of metformin. (B)Survival rates were calculated in different groups (n = 10). (C-D)The integrity of the intestinal barrier was evaluated with the serum I-FABP levels and TER. (E–F) the histopathological damage was estimated with the H&E staining and the Chiu's score classification of small intestine injury was applied to grade the histological score. (G–H) The expressions of the tight junction protein, ZO-1 and occludin, were analyzed by Western blot. Different OGD/R models were induced in Caco-2 cells as mentioned in Methods. (I)The releasing levels of LDH were detected. (J) Cell viability was measured with CCK-8 assay. The values were showed as the mean ± SEM in (C–J) (n = 6) and B(n = 10). *p < 0.05, **p < 0.01, ***p < 0.001 compared with sham group.
Metformin, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/metformin+hcl/Metformin+hydrochloride/pmc07178548-57-1-2
Average 94 stars, based on 1 article reviews
metformin - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
Biosynth Carbosynth metformin hydrochloride hcl
Maternal HFD intake during lactation leads to excessive maternal weight gain and hyperglycemia at weaning which is not affected by <t>metformin</t> treatment. (A) Schematic representation of experimental design for maternal dietary exposure, treatment interventions and offspring tissue collection at P16 or P21. (B–D) Maternal body weight throughout the lactation period in vehicle-treated, insulin-treated and metformin-treated mothers (n = 3–6/group). (E) Maternal body weight gain from P1 to P16 (n = 5–8/group). (F–H) Maternal food intake throughout the lactation period in vehicle-treated, insulin-treated and metformin-treated mothers (n = 4–6/group). (I) Maternal cumulative food intake from P1 to P16 (n = 4–6/group). (J) Maternal random blood glucose levels (mg/dl) at weaning (n = 6–13/group), (K) maternal circulating insulin levels (ng/ml) at weaning (n = 5–8/group), (L) maternal circulating leptin levels (ng/ml) at weaning (n = 6–8/group) and (M) GDF15 plasma levels (pg/ml) at weaning (n = 3–7/group). Light grey shadowed area represents treatment phase, connecting lines represent mean and SEM is represented as colour-specific surrounding fill area (B, C, D, F, G H). In data plotted as box plots (E, I, J) whiskers are min. to max., hinges of boxes are 25th and 75th percentiles, and the middle line is the median. In bar graphs (K, L, M), data are expressed as mean ± SEM with single data points. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 derived from 2-way ANOVA with repeated measures (diet x time; B, D, F, H), mixed effects model (diet x time; C, G) or 2-way ANOVA followed by Tukey's multiple comparisons (diet x treatment; E, I, J, K, L). CD/CD: gestational and lactational control diet-fed mothers, CD/HFD: gestational control diet and lactational high-fat diet-fed mothers, HFD/HFD: gestational and lactational high-fat diet-fed mothers, P: postnatal day. Mouse and food icons are from https://scidraw.io/ .
Metformin Hydrochloride Hcl, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/metformin+hcl/Metformin+HCl/pmc10792763-311-7-11
Average 93 stars, based on 1 article reviews
metformin hydrochloride hcl - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
Amneal Pharmaceuticals metformin hcl standard
Maternal HFD intake during lactation leads to excessive maternal weight gain and hyperglycemia at weaning which is not affected by <t>metformin</t> treatment. (A) Schematic representation of experimental design for maternal dietary exposure, treatment interventions and offspring tissue collection at P16 or P21. (B–D) Maternal body weight throughout the lactation period in vehicle-treated, insulin-treated and metformin-treated mothers (n = 3–6/group). (E) Maternal body weight gain from P1 to P16 (n = 5–8/group). (F–H) Maternal food intake throughout the lactation period in vehicle-treated, insulin-treated and metformin-treated mothers (n = 4–6/group). (I) Maternal cumulative food intake from P1 to P16 (n = 4–6/group). (J) Maternal random blood glucose levels (mg/dl) at weaning (n = 6–13/group), (K) maternal circulating insulin levels (ng/ml) at weaning (n = 5–8/group), (L) maternal circulating leptin levels (ng/ml) at weaning (n = 6–8/group) and (M) GDF15 plasma levels (pg/ml) at weaning (n = 3–7/group). Light grey shadowed area represents treatment phase, connecting lines represent mean and SEM is represented as colour-specific surrounding fill area (B, C, D, F, G H). In data plotted as box plots (E, I, J) whiskers are min. to max., hinges of boxes are 25th and 75th percentiles, and the middle line is the median. In bar graphs (K, L, M), data are expressed as mean ± SEM with single data points. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 derived from 2-way ANOVA with repeated measures (diet x time; B, D, F, H), mixed effects model (diet x time; C, G) or 2-way ANOVA followed by Tukey's multiple comparisons (diet x treatment; E, I, J, K, L). CD/CD: gestational and lactational control diet-fed mothers, CD/HFD: gestational control diet and lactational high-fat diet-fed mothers, HFD/HFD: gestational and lactational high-fat diet-fed mothers, P: postnatal day. Mouse and food icons are from https://scidraw.io/ .
Metformin Hcl Standard, supplied by Amneal Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/metformin+hcl/metformin+hcl+standard/10__3390_slash_molecules23092258-48-0-12
Average 90 stars, based on 1 article reviews
metformin hcl standard - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Amneal Pharmaceuticals metformin hcl extended release tablets
Maternal HFD intake during lactation leads to excessive maternal weight gain and hyperglycemia at weaning which is not affected by <t>metformin</t> treatment. (A) Schematic representation of experimental design for maternal dietary exposure, treatment interventions and offspring tissue collection at P16 or P21. (B–D) Maternal body weight throughout the lactation period in vehicle-treated, insulin-treated and metformin-treated mothers (n = 3–6/group). (E) Maternal body weight gain from P1 to P16 (n = 5–8/group). (F–H) Maternal food intake throughout the lactation period in vehicle-treated, insulin-treated and metformin-treated mothers (n = 4–6/group). (I) Maternal cumulative food intake from P1 to P16 (n = 4–6/group). (J) Maternal random blood glucose levels (mg/dl) at weaning (n = 6–13/group), (K) maternal circulating insulin levels (ng/ml) at weaning (n = 5–8/group), (L) maternal circulating leptin levels (ng/ml) at weaning (n = 6–8/group) and (M) GDF15 plasma levels (pg/ml) at weaning (n = 3–7/group). Light grey shadowed area represents treatment phase, connecting lines represent mean and SEM is represented as colour-specific surrounding fill area (B, C, D, F, G H). In data plotted as box plots (E, I, J) whiskers are min. to max., hinges of boxes are 25th and 75th percentiles, and the middle line is the median. In bar graphs (K, L, M), data are expressed as mean ± SEM with single data points. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 derived from 2-way ANOVA with repeated measures (diet x time; B, D, F, H), mixed effects model (diet x time; C, G) or 2-way ANOVA followed by Tukey's multiple comparisons (diet x treatment; E, I, J, K, L). CD/CD: gestational and lactational control diet-fed mothers, CD/HFD: gestational control diet and lactational high-fat diet-fed mothers, HFD/HFD: gestational and lactational high-fat diet-fed mothers, P: postnatal day. Mouse and food icons are from https://scidraw.io/ .
Metformin Hcl Extended Release Tablets, supplied by Amneal Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/metformin+hcl/metformin+hcl+extended+release+tablets/10__3390_slash_molecules23092258-48-4-12
Average 90 stars, based on 1 article reviews
metformin hcl extended release tablets - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Bristol Myers glucovance® (glyburide metformin hcl
Maternal HFD intake during lactation leads to excessive maternal weight gain and hyperglycemia at weaning which is not affected by <t>metformin</t> treatment. (A) Schematic representation of experimental design for maternal dietary exposure, treatment interventions and offspring tissue collection at P16 or P21. (B–D) Maternal body weight throughout the lactation period in vehicle-treated, insulin-treated and metformin-treated mothers (n = 3–6/group). (E) Maternal body weight gain from P1 to P16 (n = 5–8/group). (F–H) Maternal food intake throughout the lactation period in vehicle-treated, insulin-treated and metformin-treated mothers (n = 4–6/group). (I) Maternal cumulative food intake from P1 to P16 (n = 4–6/group). (J) Maternal random blood glucose levels (mg/dl) at weaning (n = 6–13/group), (K) maternal circulating insulin levels (ng/ml) at weaning (n = 5–8/group), (L) maternal circulating leptin levels (ng/ml) at weaning (n = 6–8/group) and (M) GDF15 plasma levels (pg/ml) at weaning (n = 3–7/group). Light grey shadowed area represents treatment phase, connecting lines represent mean and SEM is represented as colour-specific surrounding fill area (B, C, D, F, G H). In data plotted as box plots (E, I, J) whiskers are min. to max., hinges of boxes are 25th and 75th percentiles, and the middle line is the median. In bar graphs (K, L, M), data are expressed as mean ± SEM with single data points. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 derived from 2-way ANOVA with repeated measures (diet x time; B, D, F, H), mixed effects model (diet x time; C, G) or 2-way ANOVA followed by Tukey's multiple comparisons (diet x treatment; E, I, J, K, L). CD/CD: gestational and lactational control diet-fed mothers, CD/HFD: gestational control diet and lactational high-fat diet-fed mothers, HFD/HFD: gestational and lactational high-fat diet-fed mothers, P: postnatal day. Mouse and food icons are from https://scidraw.io/ .
Glucovance® (Glyburide Metformin Hcl, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/metformin+hcl/glucovance+++glyburide+metformin+hcl/us08575156-3095-72-77
Average 90 stars, based on 1 article reviews
glucovance® (glyburide metformin hcl - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Bristol Myers metformin hcl tablets
<t>Metformin</t> prevented MCT-induced pulmonary artery hypertension. ( A ) The right ventricular systolic pressure in different groups. ( B ) The right ventricle hypertrophy index in different groups. * P <0.05 vs. control group; # P <0.05 vs. MCT group.
Metformin Hcl Tablets, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/metformin+hcl/metformin+hcl+tablets/pmc04795089-26-0-6
Average 90 stars, based on 1 article reviews
metformin hcl tablets - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
LabCoat Ltd 1000 mg metformin hcl membrane coated tablets
<t>Metformin</t> prevented MCT-induced pulmonary artery hypertension. ( A ) The right ventricular systolic pressure in different groups. ( B ) The right ventricle hypertrophy index in different groups. * P <0.05 vs. control group; # P <0.05 vs. MCT group.
1000 Mg Metformin Hcl Membrane Coated Tablets, supplied by LabCoat Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/metformin+hcl/1000+mg+metformin+hcl+membrane+coated+tablets/us09060941-233-13-22
Average 90 stars, based on 1 article reviews
1000 mg metformin hcl membrane coated tablets - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Merck & Co metformin hcl
Effect of experimental diabetes and treatment with <t>metformin</t> on FBG. * indicates significant difference at P < 0.05 with group C. † indicates significant difference at P < 0.05 with group D
Metformin Hcl, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/metformin+hcl/metformin+glucophage/pmc04312800-38-17-19
Average 90 stars, based on 1 article reviews
metformin hcl - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
CDN Isotopes metformin-d6 hcl internal standard
Effect of experimental diabetes and treatment with <t>metformin</t> on FBG. * indicates significant difference at P < 0.05 with group C. † indicates significant difference at P < 0.05 with group D
Metformin D6 Hcl Internal Standard, supplied by CDN Isotopes, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/metformin+hcl/metformin+d6+hcl+internal+standard/pmc04783238-103-7-9
Average 90 stars, based on 1 article reviews
metformin-d6 hcl internal standard - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Incepta Pharmaceuticals metformin hcl
Effect of experimental diabetes and treatment with <t>metformin</t> on FBG. * indicates significant difference at P < 0.05 with group C. † indicates significant difference at P < 0.05 with group D
Metformin Hcl, supplied by Incepta Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/metformin+hcl/metformin+hcl/pmc04052803-55-24-36
Average 90 stars, based on 1 article reviews
metformin hcl - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Wockhardt limited gliclazide 5 gm
Effect of experimental diabetes and treatment with <t>metformin</t> on FBG. * indicates significant difference at P < 0.05 with group C. † indicates significant difference at P < 0.05 with group D
Gliclazide 5 Gm, supplied by Wockhardt limited, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/metformin+hcl/metformin+hcl/10__13005_slash_bpj_slash_2864-45-0-7
Average 90 stars, based on 1 article reviews
gliclazide 5 gm - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Fig. 4. Inhibition of Complex I sensitized the radioresistant glioma U87MG_F cells to radiation. (A) MTT assay was used to test the effects of rotenone on the growth of U87MG and U87MG_F cells. (B) We used 200 nM rotenone to treat U87MG, U87MG_F and U251 cells. This dose of rotenone does not influence the cell growth. The survivals of cells after treating with rotenone and 2 Gy radiation were analyzed, which showed rotenone can sensitize U87MG_F cells to 2 Gy radiation. However, rote- none did not obviously increase the sensitization of U87MG cells to ra- diation. (C) We used 12 mM metformin treat U87MG, U87MG_F and U251 cells. The survivals of cells after treating with metformin and 2 Gy radiation were analyzed, which showed metformin sensitized U87MG_F cells to 2 Gy radiation. These results demonstrate mitochondria meta- bolism play vital roles in fractioned radiation-induced radioresistance of glioma cells. (D) The Complex I inhibitor, rotenone (200 nM), increases the intracellular ROS production in U87MG and U87MG_F cells, while metformin (12 mM) decrease the ROS production. The ROS in control cells was set 1, and fold changes in the drug-treated cells were shown up. ***p < 0.001.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Article Title: Inhibition of mitochondria NADH-Ubiquinone oxidoreductase (complex I) sensitizes the radioresistant glioma U87MG cells to radiation.

doi: 10.1016/j.biopha.2020.110460

Figure Lengend Snippet: Fig. 4. Inhibition of Complex I sensitized the radioresistant glioma U87MG_F cells to radiation. (A) MTT assay was used to test the effects of rotenone on the growth of U87MG and U87MG_F cells. (B) We used 200 nM rotenone to treat U87MG, U87MG_F and U251 cells. This dose of rotenone does not influence the cell growth. The survivals of cells after treating with rotenone and 2 Gy radiation were analyzed, which showed rotenone can sensitize U87MG_F cells to 2 Gy radiation. However, rote- none did not obviously increase the sensitization of U87MG cells to ra- diation. (C) We used 12 mM metformin treat U87MG, U87MG_F and U251 cells. The survivals of cells after treating with metformin and 2 Gy radiation were analyzed, which showed metformin sensitized U87MG_F cells to 2 Gy radiation. These results demonstrate mitochondria meta- bolism play vital roles in fractioned radiation-induced radioresistance of glioma cells. (D) The Complex I inhibitor, rotenone (200 nM), increases the intracellular ROS production in U87MG and U87MG_F cells, while metformin (12 mM) decrease the ROS production. The ROS in control cells was set 1, and fold changes in the drug-treated cells were shown up. ***p < 0.001.

Article Snippet: Rotenone and metformin (Selleckchem, USA) was incubated with the cells for 24 h. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was incubated with the cells for 4 h. Culture medium was removed and 150 μL DMSO (Sangon Inc, China) was added.

Techniques: Inhibition, MTT Assay, Control

Intestinal ischemia-reperfusion injury induced intestinal barrier disruption and epithelial cell injury. Mice were performed with a temporary occlusion of SMA with an atraumatic vascular for different period and then release the clamp to allow a 120-min reperfusion to build an I/R model. (A) The experimental design of the present work. To evaluate the intestinal injury of different ischemia period, the animals were divided into four groups: the different ischemia period (30,60 and 90 min) group and sham group(n = 6). To determine the protective effect of metformin, another set of animals were administrated with metformin (20 or 40 mg/kg) or saline immediately at the end of a 60-min ischemia period. CY-04 (20 mg/kg), a specific inhibitor of NLRP3 inflammasomes, was used as a positive control for metformin. The OGD/R model was launched in Caco-2 cells. si- Txnip/Gsdmd were applied to revealed the roles of pyroptosis and TXNIP/NLRP3/GSDMD axis in the protective effect of metformin. (B)Survival rates were calculated in different groups (n = 10). (C-D)The integrity of the intestinal barrier was evaluated with the serum I-FABP levels and TER. (E–F) the histopathological damage was estimated with the H&E staining and the Chiu's score classification of small intestine injury was applied to grade the histological score. (G–H) The expressions of the tight junction protein, ZO-1 and occludin, were analyzed by Western blot. Different OGD/R models were induced in Caco-2 cells as mentioned in Methods. (I)The releasing levels of LDH were detected. (J) Cell viability was measured with CCK-8 assay. The values were showed as the mean ± SEM in (C–J) (n = 6) and B(n = 10). *p < 0.05, **p < 0.01, ***p < 0.001 compared with sham group.

Journal: Redox Biology

Article Title: Metformin protects against intestinal ischemia-reperfusion injury and cell pyroptosis via TXNIP-NLRP3-GSDMD pathway

doi: 10.1016/j.redox.2020.101534

Figure Lengend Snippet: Intestinal ischemia-reperfusion injury induced intestinal barrier disruption and epithelial cell injury. Mice were performed with a temporary occlusion of SMA with an atraumatic vascular for different period and then release the clamp to allow a 120-min reperfusion to build an I/R model. (A) The experimental design of the present work. To evaluate the intestinal injury of different ischemia period, the animals were divided into four groups: the different ischemia period (30,60 and 90 min) group and sham group(n = 6). To determine the protective effect of metformin, another set of animals were administrated with metformin (20 or 40 mg/kg) or saline immediately at the end of a 60-min ischemia period. CY-04 (20 mg/kg), a specific inhibitor of NLRP3 inflammasomes, was used as a positive control for metformin. The OGD/R model was launched in Caco-2 cells. si- Txnip/Gsdmd were applied to revealed the roles of pyroptosis and TXNIP/NLRP3/GSDMD axis in the protective effect of metformin. (B)Survival rates were calculated in different groups (n = 10). (C-D)The integrity of the intestinal barrier was evaluated with the serum I-FABP levels and TER. (E–F) the histopathological damage was estimated with the H&E staining and the Chiu's score classification of small intestine injury was applied to grade the histological score. (G–H) The expressions of the tight junction protein, ZO-1 and occludin, were analyzed by Western blot. Different OGD/R models were induced in Caco-2 cells as mentioned in Methods. (I)The releasing levels of LDH were detected. (J) Cell viability was measured with CCK-8 assay. The values were showed as the mean ± SEM in (C–J) (n = 6) and B(n = 10). *p < 0.05, **p < 0.01, ***p < 0.001 compared with sham group.

Article Snippet: Thus, Metformin (TopScience, USA, T0740) was intraperitoneal injected at the beginning of reperfusion at 40 mg/kg or 20 mg/kg and then applied an optimum I/R injury model as previous mentioned in Metformin treatment group while saline would be intraperitoneal injected in control group.

Techniques: Disruption, Saline, Positive Control, Staining, Western Blot, CCK-8 Assay, H&E Stain

Metformin protected against intestinal ischemia-reperfusion injury induced intestinal barrier disruption and cell injury. The animal models were launched with a 60-min ischemia period as mentioned. Different doses of metformin (20 or 40 mg/kg) were used to treat the mice as pervious mentioned. (A) The histological damage was evaluated with H&E staining. (B) The histological scores were calculated with the Chiu's score classification of small intestine injury . (C) The levels of I-FABP in serum were detected. (D) The TER of gut mucosae was measured. (E–F) The expressions of the tight junction protein, ZO-1 and occludin, were analyzed by Western blot. The cells were kept in a low-oxygen/glucose condition for 4 h then induced an OGD/R models as mentioned. Metformin were subjected at different dose (1 or 2 mM) (G) The releasing levels of LDH were detected. (H) Cell viability was measured with CCK-8 assay. The values were showed as the mean ± SEM(n = 5–6). *p < 0.05 compared with no-treatment group and # p < 0.05 compared with low dose group.

Journal: Redox Biology

Article Title: Metformin protects against intestinal ischemia-reperfusion injury and cell pyroptosis via TXNIP-NLRP3-GSDMD pathway

doi: 10.1016/j.redox.2020.101534

Figure Lengend Snippet: Metformin protected against intestinal ischemia-reperfusion injury induced intestinal barrier disruption and cell injury. The animal models were launched with a 60-min ischemia period as mentioned. Different doses of metformin (20 or 40 mg/kg) were used to treat the mice as pervious mentioned. (A) The histological damage was evaluated with H&E staining. (B) The histological scores were calculated with the Chiu's score classification of small intestine injury . (C) The levels of I-FABP in serum were detected. (D) The TER of gut mucosae was measured. (E–F) The expressions of the tight junction protein, ZO-1 and occludin, were analyzed by Western blot. The cells were kept in a low-oxygen/glucose condition for 4 h then induced an OGD/R models as mentioned. Metformin were subjected at different dose (1 or 2 mM) (G) The releasing levels of LDH were detected. (H) Cell viability was measured with CCK-8 assay. The values were showed as the mean ± SEM(n = 5–6). *p < 0.05 compared with no-treatment group and # p < 0.05 compared with low dose group.

Article Snippet: Thus, Metformin (TopScience, USA, T0740) was intraperitoneal injected at the beginning of reperfusion at 40 mg/kg or 20 mg/kg and then applied an optimum I/R injury model as previous mentioned in Metformin treatment group while saline would be intraperitoneal injected in control group.

Techniques: Disruption, Staining, Western Blot, CCK-8 Assay

Metformin protected against intestinal ischemia-reperfusion injury induced intestinal inflammation and pyroptosis. The I/R models were established as mentioned and the CY-09 was administered at 20 mg/kg as a positive control. (A–C) The inflammatory factors in intestinal tissues, including IL-6, IL-1β and TNF-α, were evaluated. (D–E) Pyroptosis-related proteins in intestinal tissue, including NLRP3, cleaved Caspase-1, IL-1β and IL-18, were examined by Western blot. (F–G) The expression of GSDMD in vivo was detected by Western blot. (H–I) The expression of NLRP3 was also detected in vitro by immunofluorescence. si- Gsdmd was used to inhibit the pyroptosis and revealed the relationship between metformin and pyroptosis (J) the releasing levels of LDH were detected (K) Cell viability was measured with CCK-8 assay. The values were showed as the mean ± SEM(n = 5–6). *p < 0.05 compared with no-treatment group and # p < 0.05 compared with metformin treatment group. $ p < 0.05 compared with si- Con group and & p < 0.05 compared with si- Con +OGD/R group.

Journal: Redox Biology

Article Title: Metformin protects against intestinal ischemia-reperfusion injury and cell pyroptosis via TXNIP-NLRP3-GSDMD pathway

doi: 10.1016/j.redox.2020.101534

Figure Lengend Snippet: Metformin protected against intestinal ischemia-reperfusion injury induced intestinal inflammation and pyroptosis. The I/R models were established as mentioned and the CY-09 was administered at 20 mg/kg as a positive control. (A–C) The inflammatory factors in intestinal tissues, including IL-6, IL-1β and TNF-α, were evaluated. (D–E) Pyroptosis-related proteins in intestinal tissue, including NLRP3, cleaved Caspase-1, IL-1β and IL-18, were examined by Western blot. (F–G) The expression of GSDMD in vivo was detected by Western blot. (H–I) The expression of NLRP3 was also detected in vitro by immunofluorescence. si- Gsdmd was used to inhibit the pyroptosis and revealed the relationship between metformin and pyroptosis (J) the releasing levels of LDH were detected (K) Cell viability was measured with CCK-8 assay. The values were showed as the mean ± SEM(n = 5–6). *p < 0.05 compared with no-treatment group and # p < 0.05 compared with metformin treatment group. $ p < 0.05 compared with si- Con group and & p < 0.05 compared with si- Con +OGD/R group.

Article Snippet: Thus, Metformin (TopScience, USA, T0740) was intraperitoneal injected at the beginning of reperfusion at 40 mg/kg or 20 mg/kg and then applied an optimum I/R injury model as previous mentioned in Metformin treatment group while saline would be intraperitoneal injected in control group.

Techniques: Positive Control, Tissue, Western Blot, Expressing, In Vivo, In Vitro, Immunofluorescence, CCK-8 Assay

Metformin protected against intestinal ischemia-reperfusion injury induced oxidative stress and TXNIP-NLRP3 interaction in vitro. Caco-2 cells were induced to an OGD/R model as mentioned. Metformin treated models at different dose (1 or 2 mM). (A–C) Oxidative stress was measured by SOD, GSH and MDA. (D–E) ROS was detected with a DHE staining and the ROS-positive cells were calculated by two random observers. (F–G) the expression of TXNIP was examined by Western blot. (H–I) The expression of TXNIP was also detected in vitro by immunofluorescence. (J) the co-localization of TXNIP and NLRP3 was showed by immunofluorescence. The values were showed as the mean ± SEM(n = 5–6). *p < 0.05 compared with no-treatment group and # p < 0.05 compared with low dose group.

Journal: Redox Biology

Article Title: Metformin protects against intestinal ischemia-reperfusion injury and cell pyroptosis via TXNIP-NLRP3-GSDMD pathway

doi: 10.1016/j.redox.2020.101534

Figure Lengend Snippet: Metformin protected against intestinal ischemia-reperfusion injury induced oxidative stress and TXNIP-NLRP3 interaction in vitro. Caco-2 cells were induced to an OGD/R model as mentioned. Metformin treated models at different dose (1 or 2 mM). (A–C) Oxidative stress was measured by SOD, GSH and MDA. (D–E) ROS was detected with a DHE staining and the ROS-positive cells were calculated by two random observers. (F–G) the expression of TXNIP was examined by Western blot. (H–I) The expression of TXNIP was also detected in vitro by immunofluorescence. (J) the co-localization of TXNIP and NLRP3 was showed by immunofluorescence. The values were showed as the mean ± SEM(n = 5–6). *p < 0.05 compared with no-treatment group and # p < 0.05 compared with low dose group.

Article Snippet: Thus, Metformin (TopScience, USA, T0740) was intraperitoneal injected at the beginning of reperfusion at 40 mg/kg or 20 mg/kg and then applied an optimum I/R injury model as previous mentioned in Metformin treatment group while saline would be intraperitoneal injected in control group.

Techniques: In Vitro, Staining, Expressing, Western Blot, Immunofluorescence

Knockdown of TXNIP abolished metformin-inhibited pyroptosis in vitro. Caco-2 cells were transfected with TXNIP-targeting siRNA or control siRNA. Then cells were induced as OGD/R models and received metformin treatment at different dose (1 or 2 mM). (A–B) The expression of TXNIP and pyroptosis-related proteins were detected by Western blot. (C) The levels of LDH releasing were detected. The values were showed as the mean ± SEM(n = 5–6). *p < 0.05 compared with si- Con group and #p < 0.05 compared with si- Con +OGD/R group.

Journal: Redox Biology

Article Title: Metformin protects against intestinal ischemia-reperfusion injury and cell pyroptosis via TXNIP-NLRP3-GSDMD pathway

doi: 10.1016/j.redox.2020.101534

Figure Lengend Snippet: Knockdown of TXNIP abolished metformin-inhibited pyroptosis in vitro. Caco-2 cells were transfected with TXNIP-targeting siRNA or control siRNA. Then cells were induced as OGD/R models and received metformin treatment at different dose (1 or 2 mM). (A–B) The expression of TXNIP and pyroptosis-related proteins were detected by Western blot. (C) The levels of LDH releasing were detected. The values were showed as the mean ± SEM(n = 5–6). *p < 0.05 compared with si- Con group and #p < 0.05 compared with si- Con +OGD/R group.

Article Snippet: Thus, Metformin (TopScience, USA, T0740) was intraperitoneal injected at the beginning of reperfusion at 40 mg/kg or 20 mg/kg and then applied an optimum I/R injury model as previous mentioned in Metformin treatment group while saline would be intraperitoneal injected in control group.

Techniques: Knockdown, In Vitro, Transfection, Control, Expressing, Western Blot

The mechanism map of the protective properties of metformin against intestinal ischemia-reperfusion injury via a TXNIP-NLRP3-GSDMD pathway.

Journal: Redox Biology

Article Title: Metformin protects against intestinal ischemia-reperfusion injury and cell pyroptosis via TXNIP-NLRP3-GSDMD pathway

doi: 10.1016/j.redox.2020.101534

Figure Lengend Snippet: The mechanism map of the protective properties of metformin against intestinal ischemia-reperfusion injury via a TXNIP-NLRP3-GSDMD pathway.

Article Snippet: Thus, Metformin (TopScience, USA, T0740) was intraperitoneal injected at the beginning of reperfusion at 40 mg/kg or 20 mg/kg and then applied an optimum I/R injury model as previous mentioned in Metformin treatment group while saline would be intraperitoneal injected in control group.

Techniques:

Maternal HFD intake during lactation leads to excessive maternal weight gain and hyperglycemia at weaning which is not affected by metformin treatment. (A) Schematic representation of experimental design for maternal dietary exposure, treatment interventions and offspring tissue collection at P16 or P21. (B–D) Maternal body weight throughout the lactation period in vehicle-treated, insulin-treated and metformin-treated mothers (n = 3–6/group). (E) Maternal body weight gain from P1 to P16 (n = 5–8/group). (F–H) Maternal food intake throughout the lactation period in vehicle-treated, insulin-treated and metformin-treated mothers (n = 4–6/group). (I) Maternal cumulative food intake from P1 to P16 (n = 4–6/group). (J) Maternal random blood glucose levels (mg/dl) at weaning (n = 6–13/group), (K) maternal circulating insulin levels (ng/ml) at weaning (n = 5–8/group), (L) maternal circulating leptin levels (ng/ml) at weaning (n = 6–8/group) and (M) GDF15 plasma levels (pg/ml) at weaning (n = 3–7/group). Light grey shadowed area represents treatment phase, connecting lines represent mean and SEM is represented as colour-specific surrounding fill area (B, C, D, F, G H). In data plotted as box plots (E, I, J) whiskers are min. to max., hinges of boxes are 25th and 75th percentiles, and the middle line is the median. In bar graphs (K, L, M), data are expressed as mean ± SEM with single data points. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 derived from 2-way ANOVA with repeated measures (diet x time; B, D, F, H), mixed effects model (diet x time; C, G) or 2-way ANOVA followed by Tukey's multiple comparisons (diet x treatment; E, I, J, K, L). CD/CD: gestational and lactational control diet-fed mothers, CD/HFD: gestational control diet and lactational high-fat diet-fed mothers, HFD/HFD: gestational and lactational high-fat diet-fed mothers, P: postnatal day. Mouse and food icons are from https://scidraw.io/ .

Journal: Molecular Metabolism

Article Title: Developmental metformin exposure does not rescue physiological impairments derived from early exposure to altered maternal metabolic state in offspring mice

doi: 10.1016/j.molmet.2023.101860

Figure Lengend Snippet: Maternal HFD intake during lactation leads to excessive maternal weight gain and hyperglycemia at weaning which is not affected by metformin treatment. (A) Schematic representation of experimental design for maternal dietary exposure, treatment interventions and offspring tissue collection at P16 or P21. (B–D) Maternal body weight throughout the lactation period in vehicle-treated, insulin-treated and metformin-treated mothers (n = 3–6/group). (E) Maternal body weight gain from P1 to P16 (n = 5–8/group). (F–H) Maternal food intake throughout the lactation period in vehicle-treated, insulin-treated and metformin-treated mothers (n = 4–6/group). (I) Maternal cumulative food intake from P1 to P16 (n = 4–6/group). (J) Maternal random blood glucose levels (mg/dl) at weaning (n = 6–13/group), (K) maternal circulating insulin levels (ng/ml) at weaning (n = 5–8/group), (L) maternal circulating leptin levels (ng/ml) at weaning (n = 6–8/group) and (M) GDF15 plasma levels (pg/ml) at weaning (n = 3–7/group). Light grey shadowed area represents treatment phase, connecting lines represent mean and SEM is represented as colour-specific surrounding fill area (B, C, D, F, G H). In data plotted as box plots (E, I, J) whiskers are min. to max., hinges of boxes are 25th and 75th percentiles, and the middle line is the median. In bar graphs (K, L, M), data are expressed as mean ± SEM with single data points. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 derived from 2-way ANOVA with repeated measures (diet x time; B, D, F, H), mixed effects model (diet x time; C, G) or 2-way ANOVA followed by Tukey's multiple comparisons (diet x treatment; E, I, J, K, L). CD/CD: gestational and lactational control diet-fed mothers, CD/HFD: gestational control diet and lactational high-fat diet-fed mothers, HFD/HFD: gestational and lactational high-fat diet-fed mothers, P: postnatal day. Mouse and food icons are from https://scidraw.io/ .

Article Snippet: The metformin-treated group consisted of dams receiving metformin hydrochloride (HCl) (#FM25131, Biosynth Carbosynth) into the drinking water (3 mg/ml) and the offspring were daily injected with metformin (200 mg/kg; i.p.), to ensure that they receive a similar dose of metformin as they would get in utero , as previous studies have shown the metformin levels reaching into the pups' circulation through the breast milk are almost undetectable [ ].

Techniques: Clinical Proteomics, Derivative Assay, Control

Two-way ANOVA results for <xref ref-type= Figure 1 ." width="100%" height="100%">

Journal: Molecular Metabolism

Article Title: Developmental metformin exposure does not rescue physiological impairments derived from early exposure to altered maternal metabolic state in offspring mice

doi: 10.1016/j.molmet.2023.101860

Figure Lengend Snippet: Two-way ANOVA results for Figure 1 .

Article Snippet: The metformin-treated group consisted of dams receiving metformin hydrochloride (HCl) (#FM25131, Biosynth Carbosynth) into the drinking water (3 mg/ml) and the offspring were daily injected with metformin (200 mg/kg; i.p.), to ensure that they receive a similar dose of metformin as they would get in utero , as previous studies have shown the metformin levels reaching into the pups' circulation through the breast milk are almost undetectable [ ].

Techniques:

Anti-diabetic treatments effects on offspring growth and metabolic hormone levels is dependent on maternal metabolic state. (A–C) Male offspring body weight from vehicle-treated group, from insulin-treated mothers and from metformin-treated group from P4 to P21 (n = 11–14/group). (D) Male offspring body weight at P16 and (E) body weight change from P4 to P16 (n = 16–21/group). (F) Blood glucose levels (n = 18–20/group), (G) insulin, (H) leptin, (I) ghrelin and (J) GDF15 plasma levels in P16 male offspring (n = 5–7/group). (K–M) Female offspring body weight from vehicle-treated group, from insulin-treated mothers and from metformin-treated group from P4 to P21 (n = 10–14/group). (N) Female offspring body weight at P16 and (O) body weight changes from P4 to P16 (n = 16–21/group). (P) Blood glucose levels (n = 7–18/group), (Q) insulin, (R) leptin, (S) ghrelin and (T) GDF15 plasma levels in P16 female offspring (n = 3–7/group). Connecting lines represent mean and SEM is represented as colour-specific surrounding fill area, dotted line indicates P16 time-point (A, B, C, K, L, M). In data plotted as box plots (D, E, N, O) whiskers are min. to max., hinges of boxes are 25th and 75th percentiles, and the middle line is the median. In bar graphs (F, G, H, I, J, P, Q, R, S, T), data are expressed as mean ± SEM with single data points. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 derived from 2-way ANOVA with repeated measures (diet x time; A, B, C, K, L, M) and 2-way ANOVA followed by Tukey's multiple comparisons (diet x treatment; D, E, F, G, H, I, J, N, O, P, Q, R, S, T), ##p < 0.01 compared to CD/CD/MET (T). CD/CD: gestational and lactational control diet-exposed, CD/HFD: gestational control diet and lactational high-fat diet-exposed, HFD/HFD: gestational and lactational high-fat diet-exposed.

Journal: Molecular Metabolism

Article Title: Developmental metformin exposure does not rescue physiological impairments derived from early exposure to altered maternal metabolic state in offspring mice

doi: 10.1016/j.molmet.2023.101860

Figure Lengend Snippet: Anti-diabetic treatments effects on offspring growth and metabolic hormone levels is dependent on maternal metabolic state. (A–C) Male offspring body weight from vehicle-treated group, from insulin-treated mothers and from metformin-treated group from P4 to P21 (n = 11–14/group). (D) Male offspring body weight at P16 and (E) body weight change from P4 to P16 (n = 16–21/group). (F) Blood glucose levels (n = 18–20/group), (G) insulin, (H) leptin, (I) ghrelin and (J) GDF15 plasma levels in P16 male offspring (n = 5–7/group). (K–M) Female offspring body weight from vehicle-treated group, from insulin-treated mothers and from metformin-treated group from P4 to P21 (n = 10–14/group). (N) Female offspring body weight at P16 and (O) body weight changes from P4 to P16 (n = 16–21/group). (P) Blood glucose levels (n = 7–18/group), (Q) insulin, (R) leptin, (S) ghrelin and (T) GDF15 plasma levels in P16 female offspring (n = 3–7/group). Connecting lines represent mean and SEM is represented as colour-specific surrounding fill area, dotted line indicates P16 time-point (A, B, C, K, L, M). In data plotted as box plots (D, E, N, O) whiskers are min. to max., hinges of boxes are 25th and 75th percentiles, and the middle line is the median. In bar graphs (F, G, H, I, J, P, Q, R, S, T), data are expressed as mean ± SEM with single data points. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 derived from 2-way ANOVA with repeated measures (diet x time; A, B, C, K, L, M) and 2-way ANOVA followed by Tukey's multiple comparisons (diet x treatment; D, E, F, G, H, I, J, N, O, P, Q, R, S, T), ##p < 0.01 compared to CD/CD/MET (T). CD/CD: gestational and lactational control diet-exposed, CD/HFD: gestational control diet and lactational high-fat diet-exposed, HFD/HFD: gestational and lactational high-fat diet-exposed.

Article Snippet: The metformin-treated group consisted of dams receiving metformin hydrochloride (HCl) (#FM25131, Biosynth Carbosynth) into the drinking water (3 mg/ml) and the offspring were daily injected with metformin (200 mg/kg; i.p.), to ensure that they receive a similar dose of metformin as they would get in utero , as previous studies have shown the metformin levels reaching into the pups' circulation through the breast milk are almost undetectable [ ].

Techniques: Clinical Proteomics, Derivative Assay, Control

Two-way ANOVA results for <xref ref-type= Figure 2 ." width="100%" height="100%">

Journal: Molecular Metabolism

Article Title: Developmental metformin exposure does not rescue physiological impairments derived from early exposure to altered maternal metabolic state in offspring mice

doi: 10.1016/j.molmet.2023.101860

Figure Lengend Snippet: Two-way ANOVA results for Figure 2 .

Article Snippet: The metformin-treated group consisted of dams receiving metformin hydrochloride (HCl) (#FM25131, Biosynth Carbosynth) into the drinking water (3 mg/ml) and the offspring were daily injected with metformin (200 mg/kg; i.p.), to ensure that they receive a similar dose of metformin as they would get in utero , as previous studies have shown the metformin levels reaching into the pups' circulation through the breast milk are almost undetectable [ ].

Techniques:

Metformin does not have an impact on the cell number of the two main arcuate neuronal populations. (A, A′) Representative images of TdTomato-labelled AgRP neurons and their quantification in the mid-portion of the ARH. (B, B′) Representative images of TdTomato-labelled POMC neurons and their quantification in the mid-portion of the ARH. Data are presented as mean ± SEM with single data points. Blue dots represent males and orange dots represent females. Statistical analyses were performed using two-way ANOVA. Scale bar is 100 μm. 3V: third ventricle; ARH: arcuate nucleus of the hypothalamus; CD/CD: gestational and lactational control diet-exposed; CD/HFD: gestational control diet and lactational high-fat diet-exposed; HFD/HFD: gestational and lactational high-fat diet-exposed.

Journal: Molecular Metabolism

Article Title: Developmental metformin exposure does not rescue physiological impairments derived from early exposure to altered maternal metabolic state in offspring mice

doi: 10.1016/j.molmet.2023.101860

Figure Lengend Snippet: Metformin does not have an impact on the cell number of the two main arcuate neuronal populations. (A, A′) Representative images of TdTomato-labelled AgRP neurons and their quantification in the mid-portion of the ARH. (B, B′) Representative images of TdTomato-labelled POMC neurons and their quantification in the mid-portion of the ARH. Data are presented as mean ± SEM with single data points. Blue dots represent males and orange dots represent females. Statistical analyses were performed using two-way ANOVA. Scale bar is 100 μm. 3V: third ventricle; ARH: arcuate nucleus of the hypothalamus; CD/CD: gestational and lactational control diet-exposed; CD/HFD: gestational control diet and lactational high-fat diet-exposed; HFD/HFD: gestational and lactational high-fat diet-exposed.

Article Snippet: The metformin-treated group consisted of dams receiving metformin hydrochloride (HCl) (#FM25131, Biosynth Carbosynth) into the drinking water (3 mg/ml) and the offspring were daily injected with metformin (200 mg/kg; i.p.), to ensure that they receive a similar dose of metformin as they would get in utero , as previous studies have shown the metformin levels reaching into the pups' circulation through the breast milk are almost undetectable [ ].

Techniques: Control

Two-way ANOVA results for <xref ref-type= Figure 5 ." width="100%" height="100%">

Journal: Molecular Metabolism

Article Title: Developmental metformin exposure does not rescue physiological impairments derived from early exposure to altered maternal metabolic state in offspring mice

doi: 10.1016/j.molmet.2023.101860

Figure Lengend Snippet: Two-way ANOVA results for Figure 5 .

Article Snippet: The metformin-treated group consisted of dams receiving metformin hydrochloride (HCl) (#FM25131, Biosynth Carbosynth) into the drinking water (3 mg/ml) and the offspring were daily injected with metformin (200 mg/kg; i.p.), to ensure that they receive a similar dose of metformin as they would get in utero , as previous studies have shown the metformin levels reaching into the pups' circulation through the breast milk are almost undetectable [ ].

Techniques:

Comprehensive analysis of the classical signaling pathway of metformin's mechanism of action in the hypothalamus of P16 male offspring. Relative protein expression of (A) total AMPKα levels, (B) phosphorylated-AMPKα(Thr 172 ) levels and (C) AMPK activation ratio; (D) total LKB1 levels, (E) phosphorylated-LKB1(Ser 428 ) levels and (F) LKB1 activation ratio; (G) total mTOR levels, (H) phosphorylated-mTOR(Ser 2448 ) levels and (I) mTOR activation ratio; and (J) total ACC levels, (K) phosphorylated-ACC(Ser 79 ) levels and (L) ACC activation ratio (n = 6/group). Data are presented as mean ± SEM with single data points. Statistical analyses were performed using two-way ANOVA. CD/CD: gestational and lactational control diet-exposed; CD/HFD: gestational control diet and lactational high-fat diet-exposed; HFD/HFD: gestational and lactational high-fat diet-exposed.

Journal: Molecular Metabolism

Article Title: Developmental metformin exposure does not rescue physiological impairments derived from early exposure to altered maternal metabolic state in offspring mice

doi: 10.1016/j.molmet.2023.101860

Figure Lengend Snippet: Comprehensive analysis of the classical signaling pathway of metformin's mechanism of action in the hypothalamus of P16 male offspring. Relative protein expression of (A) total AMPKα levels, (B) phosphorylated-AMPKα(Thr 172 ) levels and (C) AMPK activation ratio; (D) total LKB1 levels, (E) phosphorylated-LKB1(Ser 428 ) levels and (F) LKB1 activation ratio; (G) total mTOR levels, (H) phosphorylated-mTOR(Ser 2448 ) levels and (I) mTOR activation ratio; and (J) total ACC levels, (K) phosphorylated-ACC(Ser 79 ) levels and (L) ACC activation ratio (n = 6/group). Data are presented as mean ± SEM with single data points. Statistical analyses were performed using two-way ANOVA. CD/CD: gestational and lactational control diet-exposed; CD/HFD: gestational control diet and lactational high-fat diet-exposed; HFD/HFD: gestational and lactational high-fat diet-exposed.

Article Snippet: The metformin-treated group consisted of dams receiving metformin hydrochloride (HCl) (#FM25131, Biosynth Carbosynth) into the drinking water (3 mg/ml) and the offspring were daily injected with metformin (200 mg/kg; i.p.), to ensure that they receive a similar dose of metformin as they would get in utero , as previous studies have shown the metformin levels reaching into the pups' circulation through the breast milk are almost undetectable [ ].

Techniques: Expressing, Activation Assay, Control

Comprehensive analysis of the classical signaling pathway of metformin's mechanism of action in the hypothalamus of P16 female offspring. Relative protein expression of (A) total AMPKα levels, (B) phosphorylated-AMPKα(Thr 172 ) levels and (C) AMPK activation ratio; (D) total LKB1 levels, (E) phosphorylated-LKB1(Ser 428 ) levels and (F) LKB1 activation ratio; (G) total mTOR levels, (H) phosphorylated-mTOR(Ser 2448 ) levels and (I) mTOR activation ratio; and (J) total ACC levels, (K) phosphorylated-ACC(Ser 79 ) levels and (L) ACC activation ratio (n = 6/group). Data are presented as mean ± SEM with single data points. Statistical analyses were performed using two-way ANOVA. CD/CD: gestational and lactational control diet-exposed; CD/HFD: gestational control diet and lactational high-fat diet-exposed; HFD/HFD: gestational and lactational high-fat diet-exposed.

Journal: Molecular Metabolism

Article Title: Developmental metformin exposure does not rescue physiological impairments derived from early exposure to altered maternal metabolic state in offspring mice

doi: 10.1016/j.molmet.2023.101860

Figure Lengend Snippet: Comprehensive analysis of the classical signaling pathway of metformin's mechanism of action in the hypothalamus of P16 female offspring. Relative protein expression of (A) total AMPKα levels, (B) phosphorylated-AMPKα(Thr 172 ) levels and (C) AMPK activation ratio; (D) total LKB1 levels, (E) phosphorylated-LKB1(Ser 428 ) levels and (F) LKB1 activation ratio; (G) total mTOR levels, (H) phosphorylated-mTOR(Ser 2448 ) levels and (I) mTOR activation ratio; and (J) total ACC levels, (K) phosphorylated-ACC(Ser 79 ) levels and (L) ACC activation ratio (n = 6/group). Data are presented as mean ± SEM with single data points. Statistical analyses were performed using two-way ANOVA. CD/CD: gestational and lactational control diet-exposed; CD/HFD: gestational control diet and lactational high-fat diet-exposed; HFD/HFD: gestational and lactational high-fat diet-exposed.

Article Snippet: The metformin-treated group consisted of dams receiving metformin hydrochloride (HCl) (#FM25131, Biosynth Carbosynth) into the drinking water (3 mg/ml) and the offspring were daily injected with metformin (200 mg/kg; i.p.), to ensure that they receive a similar dose of metformin as they would get in utero , as previous studies have shown the metformin levels reaching into the pups' circulation through the breast milk are almost undetectable [ ].

Techniques: Expressing, Activation Assay, Control

Two-way ANOVA results for <xref ref-type= Figure 6 ." width="100%" height="100%">

Journal: Molecular Metabolism

Article Title: Developmental metformin exposure does not rescue physiological impairments derived from early exposure to altered maternal metabolic state in offspring mice

doi: 10.1016/j.molmet.2023.101860

Figure Lengend Snippet: Two-way ANOVA results for Figure 6 .

Article Snippet: The metformin-treated group consisted of dams receiving metformin hydrochloride (HCl) (#FM25131, Biosynth Carbosynth) into the drinking water (3 mg/ml) and the offspring were daily injected with metformin (200 mg/kg; i.p.), to ensure that they receive a similar dose of metformin as they would get in utero , as previous studies have shown the metformin levels reaching into the pups' circulation through the breast milk are almost undetectable [ ].

Techniques:

Two-way ANOVA results for <xref ref-type= Figure 7 ." width="100%" height="100%">

Journal: Molecular Metabolism

Article Title: Developmental metformin exposure does not rescue physiological impairments derived from early exposure to altered maternal metabolic state in offspring mice

doi: 10.1016/j.molmet.2023.101860

Figure Lengend Snippet: Two-way ANOVA results for Figure 7 .

Article Snippet: The metformin-treated group consisted of dams receiving metformin hydrochloride (HCl) (#FM25131, Biosynth Carbosynth) into the drinking water (3 mg/ml) and the offspring were daily injected with metformin (200 mg/kg; i.p.), to ensure that they receive a similar dose of metformin as they would get in utero , as previous studies have shown the metformin levels reaching into the pups' circulation through the breast milk are almost undetectable [ ].

Techniques:

Overview of maternal overnutrition and early metformin exposure effects on the AMPK signaling cascade in the developing hypothalamus of males and females. Maternal overnutrition affected differentially AMPK activation in a sex-specific manner. Early metformin exposure increased phosphorylation of the upstream kinase LKB1 in females, whereas downstream components of AMPK signaling were affected in males. Significant effects of diet exposure or metformin treatment on the phosphorylation of the proteins assessed in the hypothalamus of P16 males (left panel) or P16 females (right panel) are indicated by the black thick arrows. ACC: acetyl-CoA carboxylase; AMPK: AMP-activated protein kinase; LKB1: liver kinase B1; mHFD: maternal high-fat diet; mTORC1: mammalian target of rapamycin complex 1; OCT: organic cation transporter; P: postnatal day; TSC1/2: tuberous sclerosis complex 1/2.

Journal: Molecular Metabolism

Article Title: Developmental metformin exposure does not rescue physiological impairments derived from early exposure to altered maternal metabolic state in offspring mice

doi: 10.1016/j.molmet.2023.101860

Figure Lengend Snippet: Overview of maternal overnutrition and early metformin exposure effects on the AMPK signaling cascade in the developing hypothalamus of males and females. Maternal overnutrition affected differentially AMPK activation in a sex-specific manner. Early metformin exposure increased phosphorylation of the upstream kinase LKB1 in females, whereas downstream components of AMPK signaling were affected in males. Significant effects of diet exposure or metformin treatment on the phosphorylation of the proteins assessed in the hypothalamus of P16 males (left panel) or P16 females (right panel) are indicated by the black thick arrows. ACC: acetyl-CoA carboxylase; AMPK: AMP-activated protein kinase; LKB1: liver kinase B1; mHFD: maternal high-fat diet; mTORC1: mammalian target of rapamycin complex 1; OCT: organic cation transporter; P: postnatal day; TSC1/2: tuberous sclerosis complex 1/2.

Article Snippet: The metformin-treated group consisted of dams receiving metformin hydrochloride (HCl) (#FM25131, Biosynth Carbosynth) into the drinking water (3 mg/ml) and the offspring were daily injected with metformin (200 mg/kg; i.p.), to ensure that they receive a similar dose of metformin as they would get in utero , as previous studies have shown the metformin levels reaching into the pups' circulation through the breast milk are almost undetectable [ ].

Techniques: Activation Assay, Phospho-proteomics

Metformin transporters are expressed in the developing hypothalamus. (A) Oct1 , (B) Oct3 and (C) Mate1 mRNA expression in the hypothalamus across development in wild-type male mice (n = 5–8/time-point). (D) Oct1 , (E) Oct3 and (F) Mate1 mRNA expression in the hypothalamus across development in wild-type female mice (n = 4–10/time-point). Data are expressed as mean ± SEM with single data points in black dots. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared to P6, unless indicated. P-values derived from one-way ANOVA followed by Tukey's multiple comparisons. P: postnatal day, W: weeks of age.

Journal: Molecular Metabolism

Article Title: Developmental metformin exposure does not rescue physiological impairments derived from early exposure to altered maternal metabolic state in offspring mice

doi: 10.1016/j.molmet.2023.101860

Figure Lengend Snippet: Metformin transporters are expressed in the developing hypothalamus. (A) Oct1 , (B) Oct3 and (C) Mate1 mRNA expression in the hypothalamus across development in wild-type male mice (n = 5–8/time-point). (D) Oct1 , (E) Oct3 and (F) Mate1 mRNA expression in the hypothalamus across development in wild-type female mice (n = 4–10/time-point). Data are expressed as mean ± SEM with single data points in black dots. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared to P6, unless indicated. P-values derived from one-way ANOVA followed by Tukey's multiple comparisons. P: postnatal day, W: weeks of age.

Article Snippet: The metformin-treated group consisted of dams receiving metformin hydrochloride (HCl) (#FM25131, Biosynth Carbosynth) into the drinking water (3 mg/ml) and the offspring were daily injected with metformin (200 mg/kg; i.p.), to ensure that they receive a similar dose of metformin as they would get in utero , as previous studies have shown the metformin levels reaching into the pups' circulation through the breast milk are almost undetectable [ ].

Techniques: Expressing, Derivative Assay

Metformin prevented MCT-induced pulmonary artery hypertension. ( A ) The right ventricular systolic pressure in different groups. ( B ) The right ventricle hypertrophy index in different groups. * P <0.05 vs. control group; # P <0.05 vs. MCT group.

Journal: Medical Science Monitor Basic Research

Article Title: Activation of AMPK Prevents Monocrotaline-Induced Extracellular Matrix Remodeling of Pulmonary Artery

doi: 10.12659/MSMBR.897505

Figure Lengend Snippet: Metformin prevented MCT-induced pulmonary artery hypertension. ( A ) The right ventricular systolic pressure in different groups. ( B ) The right ventricle hypertrophy index in different groups. * P <0.05 vs. control group; # P <0.05 vs. MCT group.

Article Snippet: Metformin HCl tablets were obtained from Bristol-Myers Squibb (Shanghai, China).

Techniques: Control

Metformin prevented MCT-induced collagen deposition. Collagen deposition in small pulmonary arteries has been investigated by Masson’s staining. ( A ) Masson’s staining of lung tissues in different groups. ( B ) Perivascular collagen area values in different groups. Con – control. * P <0.05 vs. control group; # P <0.05 vs. MCT group.

Journal: Medical Science Monitor Basic Research

Article Title: Activation of AMPK Prevents Monocrotaline-Induced Extracellular Matrix Remodeling of Pulmonary Artery

doi: 10.12659/MSMBR.897505

Figure Lengend Snippet: Metformin prevented MCT-induced collagen deposition. Collagen deposition in small pulmonary arteries has been investigated by Masson’s staining. ( A ) Masson’s staining of lung tissues in different groups. ( B ) Perivascular collagen area values in different groups. Con – control. * P <0.05 vs. control group; # P <0.05 vs. MCT group.

Article Snippet: Metformin HCl tablets were obtained from Bristol-Myers Squibb (Shanghai, China).

Techniques: Staining, Control

Effect of experimental diabetes and treatment with metformin on FBG. * indicates significant difference at P < 0.05 with group C. † indicates significant difference at P < 0.05 with group D

Journal: Veterinary Research Forum

Article Title: An investigation on body weights, blood glucose levels and pituitary-gonadal axis hormones in diabetic and metformin-treated diabetic female rats

doi:

Figure Lengend Snippet: Effect of experimental diabetes and treatment with metformin on FBG. * indicates significant difference at P < 0.05 with group C. † indicates significant difference at P < 0.05 with group D

Article Snippet: Streptozotocin (Sigma, St. Louis, USA.) was dissolved in freshly prepared sodium citrate buffer 0.1M (pH 4.5) and metformin HCl (Merck Sante S.A.S., Lyon, France) was dissolved in sterile distilled water and administered immediately after preparation.

Techniques:

Effect of experimental diabetes and treatment with metformin on body weight. * indicates significant difference at P < 0.05 with group C

Journal: Veterinary Research Forum

Article Title: An investigation on body weights, blood glucose levels and pituitary-gonadal axis hormones in diabetic and metformin-treated diabetic female rats

doi:

Figure Lengend Snippet: Effect of experimental diabetes and treatment with metformin on body weight. * indicates significant difference at P < 0.05 with group C

Article Snippet: Streptozotocin (Sigma, St. Louis, USA.) was dissolved in freshly prepared sodium citrate buffer 0.1M (pH 4.5) and metformin HCl (Merck Sante S.A.S., Lyon, France) was dissolved in sterile distilled water and administered immediately after preparation.

Techniques:

Effect of experimental diabetes and treatment with  metformin  on blood hormones level in follicular phase of ovary (Mean ± SEM).

Journal: Veterinary Research Forum

Article Title: An investigation on body weights, blood glucose levels and pituitary-gonadal axis hormones in diabetic and metformin-treated diabetic female rats

doi:

Figure Lengend Snippet: Effect of experimental diabetes and treatment with metformin on blood hormones level in follicular phase of ovary (Mean ± SEM).

Article Snippet: Streptozotocin (Sigma, St. Louis, USA.) was dissolved in freshly prepared sodium citrate buffer 0.1M (pH 4.5) and metformin HCl (Merck Sante S.A.S., Lyon, France) was dissolved in sterile distilled water and administered immediately after preparation.

Techniques:

Effect of experimental diabetes and treatment with  metformin  on blood hormones level in luteal phase of ovary (Mean ± SEM).

Journal: Veterinary Research Forum

Article Title: An investigation on body weights, blood glucose levels and pituitary-gonadal axis hormones in diabetic and metformin-treated diabetic female rats

doi:

Figure Lengend Snippet: Effect of experimental diabetes and treatment with metformin on blood hormones level in luteal phase of ovary (Mean ± SEM).

Article Snippet: Streptozotocin (Sigma, St. Louis, USA.) was dissolved in freshly prepared sodium citrate buffer 0.1M (pH 4.5) and metformin HCl (Merck Sante S.A.S., Lyon, France) was dissolved in sterile distilled water and administered immediately after preparation.

Techniques: